Comparing oral versus intravenous calcium administration on alleviating markers of production, metabolism, and inflammation during an intravenous lipopolysaccharide challenge in mid-lactation dairy cows

Abstract

Animals, including dairy cows, develop hypocalcemia during infection. Prior independent research suggests supplementing oral Ca, but not i.v. Ca, improves multiple health metrics after immune activation. Therefore, study objectives were to directly compare the effects of administering an oral Ca bolus versus i.v. Ca on mineral and energetic metabolism variables and inflammatory parameters following an i.v. LPS challenge. Mid-lactation cows (124 ± 43 DIM) were assigned to 1 of 4 treatments: (1) saline control (CON; 4 mL of saline; n = 4), (2) LPS control (CON-LPS; 0.375 µg/kg BW; n = 6), (3) LPS with oral Ca bolus (OCa-LPS; 0.375 µg/kg BW and a 192-g bolus of Bovikalc [Boehringer Ingelheim Animal Health USA Inc., Duluth, GA] containing 43 g of Ca [71% CaCl₂ and 29% CaSO₄] supplemented at −0.5 and 6 h relative to LPS administration; n = 8), and (4) LPS with i.v. Ca (IVCa-LPS; 0.375 µg/kg BW and 500 mL of Ca-gluconate, 23% [VetOne, Boise, ID]) supplemented at −0.5 and 6 h relative to LPS infusion; n = 8). During period (P) 1 (4 d), baseline data were obtained. At the initiation of P2 (5 d), LPS and Ca supplements were administered. As anticipated, CON-LPS became hypocalcemic, but OCa-LPS and IVCa-LPS had increased ionized Ca compared with CON-LPS cows (1.11 and 1.28 vs. 0.95 ± 0.02 mmol/L, respectively). Rectal temperature increased after LPS and was additionally elevated in IVCa-LPS from 3 to 4 h (38.9 and 39.8 ± 0.1°C in CON-LPS and IVCa-LPS, respectively). Administering LPS decreased DMI and milk yield relative to CON. Circulating glucose was decreased in OCa-LPS compared with CON-LPS and IVCa-LPS during the initial hyperglycemic phase at 1 h (75.1 vs. 94.9 and 95.7 ± 3.4 mg/dL, respectively, but all LPS infused cows regardless of treatment had similar glucose concentrations thereafter, which were decreased relative to baseline during the first 12 h. Blood urea nitrogen increased after LPS but this was attenuated in OCa-LPS compared with CON-LPS and IVCa-LPS cows (8.7 vs. 10.0 and 10.4 ± 0.3 mg/dL). Glucagon increased in OCa-LPS and IVCa-LPS compared with CON-LPS cows (459 and 472 vs. 335 ± 28 pg/mL, respectively), and insulin markedly increased over time regardless of LPS treatment. Lipopolysaccharide substantially increased serum amyloid A, LPS-binding protein (LBP), and haptoglobin in all treatments, but OCa-LPS tended to have increased LBP concentrations relative to IVCa-LPS (10.7 vs. 8.6 ± 0.7 µg/mL, respectively). Several cytokines increased after LPS administration, but most temporal cytokine profiles did not differ by treatment. In summary, LPS administration intensely activated the immune system and both Ca delivery routes successfully ameliorated the hypocalcemia. The i.v. and oral Ca treatments had differential effects on multiple metabolism variables and appeared to mildly influence production responses to LPS.